Crinetics Pharmaceuticals, Inc. (CRNX) analyst actions
Rating and price-target actions on CRNX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CRNX overview →
1 measured CRNX analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Radionetics Oncology Announces Initiation of Phase 1 Radiopharmaceutical Program Against a Novel Target for Adrenocortical Carcinoma | Press release | +2.50% | -0.38% |
Keep exploring
More CRNX: earnings → · SEC filings → · CRNX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ResMed Inc. (RMD) | 485 | -0.08% | 44% |
| Auris Medical Holding AG (EARS) | 484 | -0.75% | 35% |
| Medtronic plc. Ordinary Shares (MDT) | 481 | -0.06% | 45% |
| Alkermes plc - Ordinary Shares (ALKS) | 480 | -0.03% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.